Adherence to treatment with adalimumab, golimumab and ustekinumab in patients with inflammatory bowel disease

• Κύριοι συγγραφείς: María Calvo-Arbeloa (Συγγραφέας), Ana María Insausti-Serrano (Συγγραφέας), Amaya Arrondo-Velasco (Συγγραφέας), María Teresa Sarobe-Carricas (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Elsevier, 2020-03-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Objective: Inflammatory bowel disease comprises a group of chronic relapsing inflammatory disorders affecting the bowel. In the last decade, the advent of biological drugs brought about a drastic change in the treatment of the disease. Adalimumab, golimumab and ustekinumab are three biologic agents...